# Phrontline Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phrontline-biopharma

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.phrontlinebio.com
- Latest round: Angel (Jun 1, 2022)
- Investors on record: 1

## About

Founded in 2022 and based in Shanghai, China, Phrontline Biopharma Co., Ltd., trading as Phrontline Biopharma, is a biotechnology company that focuses on developing ADCs for the tumor field. The team members have more than 10 years of experience in ADC design and development. The founder, Zaoyuan Chen, has led the development of more than 10 ADC drug pipelines. In November 2025, Phrontline Biopharma raised USD 60 million in Pre-series A funding led by new investor Lapam Capital, with participation from returning investor Decheng Capital, MED-FINE Capital, new investors Hankang Capital, Jifeng Ventures, Samsung Venture Investment, Shanghai Songqing Private Equity Fund Management, Shanghai State-owned Capital Investment Leading Fund, Sino Biopharmaceutical Limited, Xiamen C&D Emerging Industry Equity Investment and other unspecified investors.
The company is committed to optimizing dual targeting in ADC. The science and technology platform includes Synergy in Tumor MicroEnvironment (SynTume) and Bispecific dual payload ADCs (Two By Two ADC). Its dual payload platform can prolong drug response.
The company generates revenue by providing research and development services for antibody-drug conjugates(ADCs).
The funding round raised in November 2025 will be used to continuously accelerate clinical progress and global expansion, committed to bringing innovative ADC therapies to patients worldwide.

## Funding rounds

- Angel, Jun 1, 2022 — MED-FINE Capital

## Investors

- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Angel